The UK Government has recently introduced a Cancer Drugs Fund and so many of these
new drugs are now available on the NHS.
If you visit your Cancer Specialist and are prescribed one of these new advanced
drugs, your Oncologist will be able to advise you of their availability on the NHS.
To avoid any confusion, please contact WPA to discuss the cover that can be provided
prior to any treatment.
|
Brand name
|
Generic name
|
The therapeutic indication(s) licensed by the EMEA
|
References
|
|
Afinitor
|
Everolimus
|
Afinitor is indicated for the treatment of patients with advanced renal cell carcinoma,
whose disease has progressed on or after treatment with VEGF-targeted therapy.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
001038/human_med_000633.jsp
&murl=menus/medicines/medicines.jsp
|
|
Alimta®
|
Pemetrexed Disodium
|
Malignant Pleural Mesothelioma:
Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Non-small cell lung cancer:
Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000564/human_med_000638.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Avastin®
|
Bevacizumab
|
Colorectal cancer:
Avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.
Metastatic breast cancer:
Avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.
Avastin in combination with capecitabine is indicated for first-line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine.
Non-small lung cancer:
Avastin, in addition to platinum-based chemotherapy, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
Metastatic renal cell cancer:
Avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and/or metastatic renal cell cancer.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000582/human_med_000663.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Erbitux®
|
Cetuximab
|
Colorectal cancer:
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer
* in combination with irinotecan-based chemotherapy or FOLFOX4,
* as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
Squamous cell cancer of the head and neck:
Erbitux is indicated for the treatment of patients with squamous cell cancer of
the head and neck
* in combination with radiation therapy for locally advanced disease,
* in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000558/human_med_000769.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Evoltra
|
Clofarabine
|
Evoltra is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in
paediatric patients who have relapsed or are refractory after receiving at least
two prior regimens and where there is no other treatment option anticipated to result
in a durable response. Safety and efficacy have been assessed in studies of patients
< 21 years old at initial diagnosis.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000613/human_med_000773.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Glivec
|
Imatinib
|
Glivec is indicated for the treatment of:
* Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl)
positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation
is not considered as the first line of treatment.
* Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha
therapy, or in accelerated phase or blast crisis.
* Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic
leukaemia (Ph+ ALL) integrated with chemotherapy.
* Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
* Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated
with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
* Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic
leukaemia (CEL) with FIP1L1-PDGFR rearrangement.
The effect of Glivec on the outcome of bone marrow transplantation has not been
determined.
Glivec is indicated for:
* The treatment of adult patients with Kit (CD 117) positive unresectable and/or
metastatic malignant gastrointestinal stromal tumours (GIST).
* The adjuvant treatment of adult patients who are at significant risk of relapse
following resection of Kit (CD117)-positive GIST. Patients who have a low or very
low risk of recurrence should not receive adjuvant treatment.
* The treatment of adult patients with unresectable dermatofibrosarcoma protuberans
(DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible
for surgery.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000406/human_med_000808.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Iressa
|
Gefitinib
|
Iressa is indicated for the treatment of adult patients with locally advanced or
metastatic non small cell lung cancer (NSCLC) with activating mutations of EGFR
TK.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
001016/human_med_000857.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Jevtana
|
Cabazitaxel
|
Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
002018/human_med_001428.jsp
&mid=WC0b01ac058001d124
&murl=menus/medicines/medicines.jsp
|
|
MabCampath®
|
Alemtuzumab
|
MacCampath is indicated for the treatment of patients with B-cell chronic lymphocytic
leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000353/human_med_000896.jsp
&murl=menus/medicines/
medicines.jsp&mid=WC0b01ac058001d124
|
|
Mabthera
|
Rituximab
|
Non-Hodgkin´s Lymphoma:
MabThera is indicated for the treatment of previously untreated patients with stage
III-IV follicular lymphoma in combination with chemotherapy. MabThera maintenance
therapy is indicated for patients with relapsed/refractory follicular lymphoma responding
to induction therapy with chemotherapy with or without MabThera. MabThera monotherapy
is indicated for treatment of patients with stage III-IV follicular lymphoma who
are chemoresistant or are in their second or subsequent relapse after chemotherapy.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large
B cell non-Hodgkin´s lymphoma in combination with CHOP (cyclophosphamide,
doxorubicin, vincristine, prednisolone) chemotherapy.
Chronic lymphocytic leukaemia (CLL):
MabThera in combination with chemotherapy is indicated for the treatment of patients
with previously untreated and relapsed/refractory chronic lymphocytic leukaemia.
Only limited data are available on efficacy and safety for patients previously treated
with monoclonal antibodies including MabThera or patients refractory to previous
MabThera plus chemotherapy.
Rheumatoid arthritis:
MabThera in combination with methotrexate is indicated for the treatment of adult
patients with severe active rheumatoid arthritis who have had an inadequate response
or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including
one or more tumour necrosis factor (TNF) inhibitor therapies.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000165/human_med_000897.jsp
&murl=menus/medicines/
medicines.jsp&mid=WC0b01ac058001d124
|
|
Neulasta
|
Pegfilgrastim
|
Neulasta is indicated for the reduction in the duration of neutropenia and the incidence
of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy
(with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000420/human_med_000924.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Nexavar®
|
Sorafenib
|
Hepatocellular carcinoma:
Nexavar is indicated for the treatment of hepatocellular carcinoma.
Renal cell carcinoma:
Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma
who have failed prior interferon-alpha or interleukin-2 based therapy or are considered
unsuitable for such therapy.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000690/human_med_000929.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Prolia
|
Denosumab
|
Prolia is indicated in the treatment of bone loss associated with hormone ablation
in men with prostate cancer at increased risk of fractures. In men with prostate
cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral
fractures.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
001120/human_med_001324.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Removab
|
Catumaxomab
|
Removab is indicated for the intraperitoneal treatment of malignant ascites in patients
with EpCAM positive carcinomas where standard therapy is not available or no longer
feasible.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000972/human_med_001024.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Revlimid
|
Lenalidomide
|
Revlimid in combination with dexamethasone is indicated for the treatment of multiple
myeloma patients who have received at least one prior therapy.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000717/human_med_001034.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Sprycel
|
Dasatinib
|
Chronic Myeloid Leukaemia:
Sprycel is indicated for the treatment of adults with chronic, accelerated or blast
phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy
including imatinib mesilate.
Acute Lymphoblastic Leukaemia & Lymphoid Blast CML:
Sprycel is indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000709/human_med_001062.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Sutent®
|
Sunitinib
|
Gastrointestinal Stromal Tumour (GIST):
Sutent is indicated for the treatment of unresectable and/or metastatic malignant
gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment
due to resistance or intolerance.
Metastatic Renal Cell Carcinoma (MRCC)
Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma
(MRCC) in adults.
Pancreatic neuroendocrine tumours (pNET)
Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000687/human_med_001069.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Tarceva®
|
Erlotinib
|
Non-small cell lung cancer (NSCLC):
Tarceva is indicated for the treatment of patients with locally advanced or metastatic
non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
When prescribing Tarceva, factors associated with prolonged survival should be taken
into account. No survival benefit or other clinically relevant effects of the treatment
have been demonstrated in patients with EGFR- negative tumours.
Pancreatic cancer:
Tarceva in combination with gemcitabine is indicated for the treatment of patients
with metastatic pancreatic cancer.
When prescribing Tarceva, factors associated with prolonged survival should be taken
into account. No survival advantage could be shown for patients with locally advanced
disease.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000618/human_med_001077.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Tasigna
|
Nilotinib
|
Tasigna is indicated for the treatment of adults with chronic phase and accelerated
phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) with
resistance or intolerance to prior therapy including imatinib. Efficacy data in
patients with CML in blast crisis are not available.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000798/human_med_001079.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Temodol^
|
Temozolomide
|
Temodol is indicated for the treatment of adult patients with newly-diagnosed glioblastoma
multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy
treatment.
Temodol is indicated for the treatment of children from the age of three years,
adolescents and adult patients with malignant glioma, such as glioblastoma multiforme
or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
001126/human_med_001226.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Torisel
|
Tesirolimus
|
Torisel is indicated for the first-line treatment of patients with advanced renal
cell carcinoma (RCC) who have at least three of six prognostic risk factors.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000799/human_med_001098.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Tyverb®
|
Lapatanib
|
Tyverb is indicated for the treatment of patients with breast cancer, whose tumours
overexpress HER2 (ErbB2);
* in combination with capecitabine for patients with advanced or metastatic disease
with progression following prior therapy, which must have included anthracyclines
and taxanes and therapy with trastuzumab in the metastatic setting.
* in combination with an aromatase inhibitor for postmenopausal women with hormone
receptor positive metastatic disease, not currently intended for chemotherapy. The
patients in the registration study were not previously treated with trastuzumab
or an aromatase inhibitor.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000795/human_med_001120.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Vectibix
|
Panitumumab
|
Vectibix is indicated for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC):
* in first-line in combination with FOLFOX
* in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
* as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000741/human_med_001128.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Velcade®
|
Bortezomib
|
Velcade in combination with melphalan and prednisone is indicated for the treatment
of patients with previously untreated multiple myeloma who are not eligible for
high-dose chemotherapy with bone marrow transplant.
Velcade is indicated as mono-therapy for the treatment of progressive multiple myeloma
in patients who have received at least 1 prior therapy and who have already undergone
or are unsuitable for bone marrow transplantation.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000539/human_med_001130.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Votrient
|
Pazopanib
|
Votrient is indicated for the first line treatment of advanced Renal Cell Carcinoma
(RCC) and for patients who have received prior cytokine therapy for advanced disease.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
001141/human_med_001337.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Votubia
|
Everolimus
|
Votubia is indicated for the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.
The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
002311/human_med_001484.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Xgeva
|
Denosumab
|
Xgeva is indicated in the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
002173/human_med_001463.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Yervoy
|
Ipilimumab
|
Yervoy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
002213/human_med_001465.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Yondelis
|
Trabectedin
|
Sarcoma:
Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma,
after failure of anthracyclines and ifosfamide, or who are unsuited to receive these
agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
Ovarian cancer:
Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated
for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000773/human_med_001165.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Zevalin®
|
90Y-ibritumomab tiuxetan
|
Follicular Lymphoma:
The [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission
induction in previously untreated patients with follicular lymphoma. The benefit
of Zevalin following rituximab in combination with chemotherapy has not been established.
Non-Hodgkin´s Lymphoma:
The [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients
with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin´s
lymphoma (NHL).
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000547/human_med_001178.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Zometa
|
Zoledronic Acid
|
Zometa is indicated for the prevention of skeletal related events (pathological
fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia)
in patients with advanced malignancies involving bone.
Treatment of tumour-induced hypercalcaemia (TIH).
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
000336/human_med_001182.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
|
Zytiga
|
Abiraterone
|
Zytiga is indicated with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
|
http://www.ema.europa.eu/
ema/index.jsp?curl=pages/
medicines/human/medicines/
002321/human_med_001499.jsp
&murl=menus/medicines/medicines.jsp
&mid=WC0b01ac058001d124
|
^ Other brands of Temozolomide are also available under a similar license.